Raymond F. Schinazi

Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and co- Director of the HIV Cure Scientific Working Group for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. Schinazi has authored over 500 peer- reviewed papers and 7 books and holds over 100 issued US patents, which have resulted in 26 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine), LdT (telbivudine), and most recently the precursor of sofosbuvir (Sovaldi), which are approved by the US FDA. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented. Dr. Schinazi served on the Presidential Commission on AIDS.

He is the recipient of numerous awards including the 2015 William S. Middleton Award from the Department of Veterans Affairs, the 2016 Humanitarian Award from the Institute of Human Virology, the 2016 Scrip Lifetime Achievement Award, State of the Art Award from the 2017 Paris Hepatology Conference, and 2017 Excellence Prize from Journées Québécoises, McGill University. In 2018 he received the Global Hepatitis Award from the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). He serves as a Senior Advisor for the International Coalition to Eliminate HBV (ICE-HBV). He is also a Fellow of the American Society of Microbiology. In September 2018, Dr. Schinazi received France’s highest civilian honor, Chevalier de la Légions D’honneur for saving millions of lives globally. Dr. Schinazi serves as Trustee on the amfAR Board of Directors. He is internationally recognized as one of the most influential persons in the life science sector.